---
aliases: [Insilico]
---
#actor #biotech #ai #drugdiscovery #hongkong #public

**Insilico Medicine** — First AI drug to Phase 2. Rentosertib proof-of-concept. HK IPO (Dec 2025). [[Sanofi]] $1.2B deal.

---

## Why Insilico matters

| Metric | Value |
|--------|-------|
| IPO | **HKD 2.28B** (Dec 2025) |
| Exchange | [[HKEX]] (largest biotech IPO 2025) |
| Milestone | **First AI drug Phase 2 success** |
| [[Sanofi]] deal | $1.2B potential |

---

## Rentosertib — First AI drug success

| Metric | Value |
|--------|-------|
| [[Target]] | TNIK inhibitor |
| Indication | Idiopathic pulmonary fibrosis (IPF) |
| Discovery | Fully AI-generated |
| Phase 2a result | **Met primary endpoint** |
| Efficacy | Dose-dependent FVC improvement (+98.4mL at 60mg) |
| Publication | Nature Medicine (May 2025) |
| USAN naming | Official drug name assigned |

**Significance:** First clinical proof-of-concept for AI-discovered drug.

---

## Pharma.AI platform

| Module | Function |
|--------|----------|
| PandaOmics | [[Target]] discovery |
| Chemistry42 | Generative molecule design |
| inClinico | Clinical trial prediction |

**End-to-end:** [[Target]] → molecule → clinical candidate in ~18 months.

---

## Major partnerships

| Partner | Deal | Value |
|---------|------|-------|
| **[[Sanofi]]** | 6 drug candidates | $1.2B (milestones) |
| **Fosun Pharma** | Co-development | [[China]] rights |
| **[[Eli Lilly]]** | Discovery collaboration | Undisclosed |

**Validation:** Blue-chip pharma partnerships confirm platform value.

---

## Pipeline

| Program | Indication | Status |
|---------|------------|--------|
| **Rentosertib** | IPF | Phase 2b planned |
| ISM3091 | IBD | Phase 1 |
| ISM5939 | Oncology | Preclinical |
| [[Sanofi]] programs | Immunology/oncology | Discovery |

---

## Hong Kong IPO (Dec 2025)

| Metric | Value |
|--------|-------|
| Date | Dec 30, 2025 |
| Raised | HKD 2.28B (~$290M) |
| Listing rule | Chapter 8.05 |
| Significance | First AI biotech on [[HKEX]] Main Board |

---

## Leadership

| Role | Name |
|------|------|
| Founder/CEO | Alex Zhavoronkov, PhD |
| Focus | Aging, oncology, fibrosis |

---

## Investment case

**Bull:**
- First AI drug Phase 2 success
- [[Sanofi]] $1.2B validation
- Pharma.AI platform proven
- IPO provides capital
- [[China]] + global strategy

**Bear:**
- Still no approved drug
- Path to profitability unclear
- Competition intensifying
- Regulatory uncertainty
- [[China]] geopolitical risk

---

## Quick stats

| Metric | Value |
|--------|-------|
| Exchange | [[HKEX]] |
| IPO | Dec 2025 |
| Lead drug | Rentosertib |
| Focus | AI drug discovery |

---

## Related

- [[AI drug discovery]] — concept
- [[Recursion]] — competitor
- [[Isomorphic Labs]] — competitor
- [[Biopharma]] — sector

---

## Sources

- [Nature Medicine: Rentosertib trial](https://www.nature.com/articles/s41591-025-03743-2)
- [Insilico HK IPO](https://www.prnewswire.com/news-releases/insilico-medicine-lists-on-hong-kong-stock-exchange-showing-ai-drug-discovery-momentum-with-2025s-largest-hong-kong-biotech-ipo-302650606.html)
- [[[Sanofi]] deal](https://pharmaphorum.com/news/sanofi-signs-1-2bn-research-alliance-with-ai-specialist-insilico)

*Created 2026-01-09*
